Skip to main content

Navigation group

Type at least 3 characters
1,722 articles

Articles

Methods

Published on 12 Jan 2023

Protocol for a multicenter, double-blind, randomized, placebo-controlled phase III trial of the inhaled β2-adrenergic receptor agonist salbutamol for transient tachypnea of the newborn (the REFSAL trial)

in Neonatology

  • Dariusz Madajczak
  • Thierry Daboval
  • Ryszard Lauterbach
  • Beata Łoniewska
  • Witold Błaż
  • Tomasz Szczapa
  • Iwona Sadowska-Krawczenko
  • Marzena Michalak-Kloc
  • Helena Sławska
  • Maria Borszewska-Kornacka
Protocol for a multicenter, double-blind, randomized, placebo-controlled phase III trial of the inhaled β2-adrenergic receptor agonist salbutamol for transient tachypnea of the newborn (the REFSAL trial)
Frontiers in Pediatrics
doi 10.3389/fped.2022.1060843
  • 4,154 views
  • 2 citations